Patents Assigned to Ruprecht Karls Universitat
-
Patent number: 11964015Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.Type: GrantFiled: April 9, 2021Date of Patent: April 23, 2024Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAT HEIDELBERGInventors: Barbara Leuchs, Antonio Marchini, Jean Rommelaere, Assia Angelova, Dirk Jager, Wolfgang Wick, Michael Dahm
-
Publication number: 20230069933Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding at least one of (i) a tumor antigen, (ii) a fragment of a tumor antigen, and (iii) a variant of (i) or (ii). The present invention further relates to a polynucleotide encoding said recombinant virus of the family Paramyxoviridae and to a host cell comprising said recombinant virus of the family Paramyxoviridae and/or said polynucleotide encoding said recombinant virus of the family Paramyxoviridae. Moreover, the present invention relates to a method for activating immune cells with antitumor activity in a sample comprising cancer cells and to further means, methods, and uses related to the present invention.Type: ApplicationFiled: May 18, 2022Publication date: March 9, 2023Applicant: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERGInventors: Elena CZINK, Christine ENGELAND, Guy UNGERECHTS
-
Patent number: 11401304Abstract: The present invention relates to cyclic NTCP targeting peptides which are preS-derived peptides of hepatitis B virus (HBV). The present invention further relates to pharmaceutical compositions comprising at least one cyclic peptide. The present invention further relates to medical uses of said cyclic peptides and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a liver disease or condition and/or the inhibition of HBV and/or HDV infection.Type: GrantFiled: December 15, 2016Date of Patent: August 2, 2022Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Stephan Urban, Yi Ni, Walter Mier
-
Patent number: 11369669Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding at least one of (i) a tumor antigen, (ii) a fragment of a tumor antigen, and (iii) a variant of (i) or (ii). The present invention further relates to a polynucleotide encoding said recombinant virus of the family Paramyxoviridae and to a host cell comprising said recombinant virus of the family Paramyxoviridae and/or said polynucleotide encoding said recombinant virus of the family Paramyxoviridae. Moreover, the present invention relates to a method for activating immune cells with antitumor activity in a sample comprising cancer cells and to further means, methods, and uses related to the present invention.Type: GrantFiled: October 16, 2017Date of Patent: June 28, 2022Assignee: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERGInventors: Elena Czink, Christine Engeland, Guy Ungerechts
-
Patent number: 11324788Abstract: Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.Type: GrantFiled: March 20, 2020Date of Patent: May 10, 2022Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Barbara Leuchs, Karsten Geletneky, Jean Rommelaere, Christiane Dinsart, Michael Dahm, Ottheinz Krebs
-
Patent number: 11320438Abstract: Tryptophan degradation is a key metabolic pathway controlling immune reactions and evidence suggests that during cancer progression generation of tryptophan metabolites may be fundamental for immune escape promoting the malignant phenotype of cancer cells in an autocrine fashion. The present invention relates to methods of measuring mass tag labelled tryptophan and metabolites thereof and methods using the labelled molecules for monitoring in a subject the effectiveness of a treatment and of disease recurrence after treatment, for stratifying patients and for diagnosing suppression of an immune response in a subject.Type: GrantFiled: October 31, 2016Date of Patent: May 3, 2022Assignees: ELECTROPHORETICS LIMITED, RUPRECHT-KARLS-UNIVERSITAT, DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Sasa Koncarevic, Karsten Kuhn, Peter Schulz-Knappe, Ian Hugo Pike, Christiane Opitz, Michael Platten
-
Patent number: 11312943Abstract: The present invention relates to Abhydrolase containing domain 5 (ABHD5) and N-terminal fragments of HDAC4 (HDAC4-NT) and variants of the aforementioned peptides for the treatment and prevention of heart failure. The present invention further provides vectors for the cardiomyocyte-specific expression of said peptides and a test system comprising ABHD5 for the identification of novel compounds which are useful for the treatment of heart failure.Type: GrantFiled: January 29, 2018Date of Patent: April 26, 2022Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Johannes Backs, Zegeye Jebessa, Lorenz Lehmann, Hugo Katus, Oliver Müller
-
Patent number: 11274132Abstract: The present invention relates to a combined preparation comprising (i) a modulator of pyruvate kinase M2 (PKM2) activity, and (ii) an agent providing high mobility group box 1 (HMGB1) polypeptide or a derivative thereof. The present invention also relates to the aforesaid combined preparation for use as a medicament and for use in the treatment of inappropriate cellular proliferation, preferably in the treatment of cancer. Moreover, the present invention relates to a method for determining whether a subject suffering from inappropriate cellular proliferation is amenable to a treatment comprising administration of a modulator of PKM2 activity as the only PKM2 inhibitor and to treatment methods related thereto.Type: GrantFiled: December 12, 2016Date of Patent: March 15, 2022Assignee: Ruprecht-Karls-Universität HeidelbergInventors: Georg Gdynia, Wilfried Roth
-
Patent number: 11202833Abstract: The present invention relates to cyclic peptide compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine-containing protein. Preferred scavenger compounds are said cyclic peptides comprising a specific amino acid motif and a hydrophobic modification, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the cyclic peptides as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the cyclic peptides for the prevention and/or treatment of a disease caused by or associated with methylglyoxal (MG) and/or reactive carbonyl species (RCS), in particular caused by or associated with elevated MG levels, such as diabetes and its associated complications, cardiovascular diseases and obesity.Type: GrantFiled: November 6, 2017Date of Patent: December 21, 2021Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Sebastian Brings, Thomas H. Fleming, Walter Mier, Peter P. Nawroth
-
Patent number: 11045564Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).Type: GrantFiled: August 26, 2019Date of Patent: June 29, 2021Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
-
Patent number: 11027013Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.Type: GrantFiled: October 1, 2018Date of Patent: June 8, 2021Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAT HEIDELBERGInventors: Barbara Leuchs, Antonio Marchini, Jean Rommelaere, Assia Angelova, Dirk Jager, Wolfgang Wick, Michael Dahm
-
Patent number: 10967044Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.Type: GrantFiled: February 7, 2019Date of Patent: April 6, 2021Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Volker Cleeves, Stephan Urban, Ralf Kubitz
-
Patent number: 10941451Abstract: The present invention relates to panels of methylation and mi RNA marker as well as their use in the prognosing, diagnosing and/or treatment of cancer, means for detecting said marker, kits comprising said means, and devices for analysing the marker panel.Type: GrantFiled: February 24, 2016Date of Patent: March 9, 2021Assignee: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERGInventors: Barbara Burwinkel, Rongxi Yang, Andreas Schneeweiss
-
Publication number: 20210060102Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) bevacizumab and the use of said composition for treatment of cancer, e.g., a solid tumor.Type: ApplicationFiled: October 26, 2020Publication date: March 4, 2021Applicants: Deutsches Krebsforschungszentrum, RUPRECHT-KARLS-UNIVERSITÄTInventors: Karsten Geletneky, Jean Rommelaere, Wolfgang Wick, Antje Wick, Michael Dahm
-
Patent number: 10792329Abstract: The present invention relates to S100 protein and nuclei acids encoding S100 protein for enhancing the cardiac power as well as vectors and pharmaceuticals comprising the same and uses thereof.Type: GrantFiled: October 1, 2014Date of Patent: October 6, 2020Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Hugo Katus, Patrick Most
-
Patent number: 10703796Abstract: The present invention relates to compounds, pharmaceutical compositions and methods for treating different forms of cancer and angiogenesis related diseases using cyclic peptides.Type: GrantFiled: December 7, 2015Date of Patent: July 7, 2020Assignees: AMCURE GMBH, RUPRECHT-KARLS-UNIVERSITÄTInventors: Alexandra Matzke-Ogi, Véronique Orian-Rousseau, Uwe Haberkorn, Thomas Lindner, Walter Mier
-
Patent number: 10682402Abstract: Described is a vaccine for prevention and treatment of cancer characterized by microsatellite instability (MSI). The vaccine contains an MSI-specific frameshift peptide (FSP) generating humoral and cellular responses against tumor cells or a nucleic acid encoding said FSP. The vaccine of the present invention is particularly useful for the prevention/treatment of colorectal cancer, endometrial cancer, gastric cancer or small bowel cancer.Type: GrantFiled: July 31, 2017Date of Patent: June 16, 2020Assignee: Ruprecht-Karls-Universität HeidelbergInventors: Matthias Kloor, Miriam Reuschenbach, Magnus von Knebel-Doeberitz
-
Patent number: 10624935Abstract: Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.Type: GrantFiled: December 4, 2017Date of Patent: April 21, 2020Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Barbara Leuchs, Karsten Geletneky, Jean Rommelaere, Christiane Dinsart, Michael Dahm, Ottheinz Krebs
-
Patent number: 10618947Abstract: The present invention relates to a novel Hepatitis B virus (HBV) and/or Hepatitis D virus (HDV) receptor and its use for the development of cells, cell lines and non-human animals that are susceptible to HBV and/or HDV infection and can be used for immunological studies and/or for the screening of drugs, post-entry restriction factors and host dependency factors. It further relates to the use of the receptor for the identification of compounds useful in the treatment of HBV and/or HDV infection.Type: GrantFiled: November 12, 2013Date of Patent: April 14, 2020Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Stephan Urban, Yi Ni
-
Patent number: 10548960Abstract: The present invention relates to polypeptides or fragments thereof for use as malaria vaccines. It also relates to nucleic acid molecules coding for the polypeptides of the invention. It further relates to compositions comprising such polypeptides or fragments thereof or the nucleic acid molecules, in particular combinations of such polypeptides or fragments thereof, and the use of such compositions as malaria vaccines.Type: GrantFiled: September 23, 2016Date of Patent: February 4, 2020Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Johannes Pfeil, Kirsten Heiss, Ann-Kristin Müller